Cubist Pharmaceuticals Given “Buy” Rating at Aegis (CBST)
Cubist Pharmaceuticals Given “Buy” Rating at Aegis (CBST)
Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in …
Read more on WKRB News
MLV & Co. Increases Galectin Therapeutics Price Target to .00 (GALT)
Analysts at Aegis raised their price target on shares of Galectin Therapeutics from $ 16.00 to $ 32.00 in a research note on Monday, February 10th. They now have a buy rating on the stock. Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage …
Read more on WKRB News
Cubist Pharmaceuticals Rating Reiterated by Aegis (CBST)
Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in …
Read more on Mideast Time
More Aegis Therapies Information…